Anthropic to Buy AI Biotech Startup Coefficient Bio for $400 Million

Anthropic has increasingly extended its generative AI capabilities into healthcare and life sciences. Drug development involves vast volumes of biological data, clinical trial information and regulatory documents, and AI could shorten the analysis process. The acquisition of AI biotech startup Coefficient Bio shows Anthropic moving beyond general-purpose models into the high-value specialist research market.

As of July 20, 2026, Anthropic planned to acquire Coefficient Bio for about $400 million. Coefficient Bio's team will join Anthropic's healthcare and life sciences group. The companies expect to use AI to improve drug-development workflows and help shape clinical trial and regulatory strategies, further strengthening Anthropic's research capabilities in biotechnology.